- Acoramidis is a selective small molecule that is orally administered. ATTR-CM is a progressive, restrictive cardiomyopathy that leads to heart failure. BridgeBio Cardiorenal chief medical officer Dr Jonathan The post BridgeBio’s...
- The FDA’s approval adds to its five prior approvals and is based on positive outcomes from the CABINET Phase III trial. CABINET is a multicentre, randomised, double-blinded, placebo-controlled The post US FDA approves Exelixis’...
- A scientific technique that rapidly increases the body's production of anti-inflammatory cells promoted healing from heart attacks in mice, according to a new study by investigators from the Smidt Heart Institute at Cedars-Sinai. Once...
- Bayer and Suzhou Puhe BioPharma Co., Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma's oral, small molecule PRMT5 inhibitor that selectively targets...
- This condition, caused by genetic mutations in the LEPR gene, leads to disrupted melanocortin-4 receptor (MC4R) signalling, resulting in extreme, constant hunger and severe early-onset obesity. PL7737, an The post US FDA grants orphan...
- The treatment, designed to be administered either as an injectable or an oral medication, utilises the regulation of the brain’s nitric oxide (NO) levels to influence neurological function. The post NeuroNOS secures funding for autism...
- The centre will focus on the early detection of diseases and design treatments for improved patient outcomes using precision medicine. Metabolomics, the study of small molecules or metabolites, The post Duke-NUS and NUS Medicine launch...
- The therapy claims to be the only oral inhibitor targeting the alternative complement pathway, specifically addressing what is believed to be the root cause of the disease. Usually The post FDA approves Novartis’ Fabhalta for C3...
- Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative disorders like Parkinson's disease, and other serious illnesses. Now, a new study from Scripps Research...
- Among other functions, the NK cells (Natural Killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot overcome the tumour’s defense mechanism...
- Scientists from Johns Hopkins Medicine and eight other institutions in the United States, Africa and Europe say they have identified a potential new gene target that could be edited to treat sickle cell disease, an inherited blood...
- AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use...
- This collaboration leverages Porton Advanced’s cell and gene therapy manufacturing offerings and Artemis cell receptor as well as the E‑ALPHA antibody discovery platforms of Eureka. Through this partnership, Porton Advanced The...
- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078). Under the terms of this agreement, the two...
- This one-time-day cream claims to offer a non-steroidal alternative that is tailored for quick relief from itch and inflammation, with a suitability for long-term usage. Arcutis Canada general The post Health Canada approves Arcutis’...
- This investigational medicine is stated to be the “first” ribonucleic acid (RNA) editing development candidate from the company’s Oligonucleotide Promoted Editing of RNA (OPERA) platform. Korro Bio chief The post FDA grants orphan drug...
- The investment also comprises C$60m in funding from the Canadian federal government. Delpharm will manufacture sterile injectable drugs at the Boucherville site and bolster its local supply chain. The The post Delpharm plans $140m...
- Physical fitness and increasing muscle strength could reduce the mortality rate for cancer patients by between 31% to 46%, new research from Edith Cowan University (ECU) has found. Around 20 million new cancer cases were reported in...
- Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalisation if they stop taking heart failure medications. This is according to...
- A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered - which could help drug delivery in cancer treatment. In a paper published in PNAS, researchers at King's College London...
- The human gut is home to trillions of bacteria that play vital roles in digestion, immunity, and overall health. When this microbial balance is disturbed, it can contribute to the development of chronic diseases like ulcerative colitis...
- Bayer and Hurdle have published groundbreaking research that represents a great advancement in aging research. The research introduces and validates a novel saliva-based DNA methylation biomarker designed to quantify systemic chronic...
- A common perception is that not all alcoholic beverages are alike. Red wine, for instance, is often considered a healthier choice, with many believing its high resveratrol content - an antioxidant with anti-inflammatory properties -...
- The herb rosemary has long been linked with memory: "There's rosemary, that's for remembrance," says Ophelia in Shakespeare's Hamlet. So it is fitting that researchers would study a compound found in rosemary and sage - carnosic acid -...
- Innovative insights into the role of ferroptosis, a unique form of programmed cell death, are reshaping the landscape of disease treatment. This growing field highlights how Traditional Chinese Medicine (TCM) can effectively modulate...
- The NHS could prevent thousands more heart attacks and strokes every year by offering everyone in the UK aged 50 and over a single "polypill" combining a statin and three blood pressure lowering drugs, according to academics from UCL. In...
- A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked...
- Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells hijack various cellular functions to find and exploit energy and other resources, including a group of enzymes that...
- A research team led by Prof. LIU Chenli from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (CAS) and Prof. XIAO Yichuan from the Shanghai Institute of Nutrition and Health of CAS elucidated the...
- Can a drug that's used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have secured a patent for the anti-malarial drug pyronaridine to do just that. Pyronaridine has been used to treat...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22